|
|
|
|
|
|
|
Biocryst Pharma Inc (BCRX)
|
|
4.9 -0.01 (-0.2%)
|
04-23 16:00
|
|
Open:
|
4.95
|
Pre. Close:
|
4.91
|
|
High:
|
4.9842
|
Low:
|
4.79
|
|
Volume:
|
325,105
|
Market Cap:
|
483M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
4.986 - 5.011
|
5.011 - 5.034
|
|
Low:
|
4.72 - 4.75
|
4.75 - 4.779
|
|
Close:
|
4.844 - 4.892
|
4.892 - 4.94
|
|
|
|
Technical analysis (as of: 2018-04-23 4:27:23 PM)
|
|
Overall:
|
|
|
Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.
|
|
Target:
|
Six months: 5.93 One year: 6.32
|
|
Support:
|
Support1: 4.53 Support2: 3.77
|
|
Resistance:
|
Resistance1:
5.07 Resistance2: 5.41
|
|
Pivot:
|
4.92 
|
|
Moving Averages:
|
MA(5): 4.99  MA(20): 4.92
MA(100): 5.05 MA(250): 5.16
|
|
MACD:
|
MACD(12,26):
-0.03 Signal(12,26,9): -0.04
|
|
%K %D:
|
%K(14,3): 46.16 %D(3): 57.42
|
|
RSI:
|
RSI(14): 47.42
|
|
52-Week:
|
High: 7.39
Low: 3.95 Change(%): -24.5
|
|
Average Vol(K):
|
3-Month: 100828
10-Days 58170
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.BCRX has closed above bottom band by 46.8%. Bollinger Bands are 20.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-04-10T08:19:35-04:00
BioCryst and Idera postpone shareholder meetings for merger vote until July 10
2018-04-10T07:30:00-04:00
BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger
2018-04-02T08:00:00-04:00
BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals
2018-03-16T08:00:00-04:00
Your Daily Pharma Scoop: Abeona Update, Alexion Data, Solid Biosciences Setback
2018-03-15T09:47:50-04:00
BioCryst launches late-stage study of BCX7353 in HAE
2018-03-02T08:00:00-05:00
Your Daily Pharma Scoop: Portola Drops On AndexXa Update, NovaVax Top-Line Results, Idera Commences Late-Stage Study With IMO-2125
2018-02-28T10:18:29-05:00
BioCryst commences long-term safety study of BCX7353 in HAE patients; shares up 2%
2018-02-27T19:38:04-05:00
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q4 2017 Results - Earnings Call Transcript
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
